December 8, 2026, 10:30 AM – 12:00 PM EST
For more than two decades, cancer vaccines delivered striking preclinical data but mostly correlative immune responses, with little meaningful survival benefit. Checkpoint inhibitors changed that. They supplied the missing countermeasure to the immunosuppressive tumor microenvironment, and evolving clinical and regulatory pathways now let developers move earlier than late-line settings. Data this year has strengthened the case for both the clinical utility and the commercial viability of cancer vaccines.
Join vaccine and IO experts and leaders from innovative biotechs for a candid discussion of the current state of the art. We’ll cover what’s driving and limiting the field, and what to expect through 2027 and beyond.
What we’ll discuss
- Core learnings from the past two decades, and the past two years, on platforms, adjuvants, and delivery systems
- Near-term approvals for personalized vaccines, and the status of “off-the-shelf” approaches
- Progress in identifying and predicting the most immunogenic tumor antigens, personalized vs. off-the-shelf
- What’s next for RNA delivery, including self-replicating and circular RNA
- How developers are tackling immunosuppressive TMEs, immune escape, and antigen spreading
You will learn:
- Commercial considerations to improve PoS, ROI, and value inflection for pre- and peri-POC programs
- Key insights on antigen identification, tumor/patient selection, and delivery technologies
- Critical clinical development considerations, including combination, partnering, and regulatory strategies